PortalPublikationenClaudin-1 upregulation is associated with favorable tumor fe...

Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer

Standard

Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. / Kind, Simon; Büscheck, Franziska; Höflmayer, Doris; Hube-Magg, Claudia; Kluth, Martina; Tsourlakis, Maria Christina; Steurer, Stefan; Clauditz, Till S; Luebke, Andreas M; Burandt, Eike; Wilczak, Waldemar; Hinsch, Andrea; Dum, David; Weidemann, Sören; Fraune, Christoph; Beyer, Burkhard; Steuber, Thomas; Huland, Hartwig; Graefen, Markus; Fisch, Margit; Simon, Ronald; Sauter, Guido; Schlomm, Thorsten; Minner, Sarah; Eichenauer, Till.

in: WORLD J UROL, Jahrgang 38, Nr. 9, 09.2020, S. 2185-2196.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kind, S, Büscheck, F, Höflmayer, D, Hube-Magg, C, Kluth, M, Tsourlakis, MC, Steurer, S, Clauditz, TS, Luebke, AM, Burandt, E, Wilczak, W, Hinsch, A, Dum, D, Weidemann, S, Fraune, C, Beyer, B, Steuber, T, Huland, H, Graefen, M, Fisch, M, Simon, R, Sauter, G, Schlomm, T, Minner, S & Eichenauer, T 2020, 'Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer', WORLD J UROL, Jg. 38, Nr. 9, S. 2185-2196. https://doi.org/10.1007/s00345-019-03017-w

APA

Kind, S., Büscheck, F., Höflmayer, D., Hube-Magg, C., Kluth, M., Tsourlakis, M. C., Steurer, S., Clauditz, T. S., Luebke, A. M., Burandt, E., Wilczak, W., Hinsch, A., Dum, D., Weidemann, S., Fraune, C., Beyer, B., Steuber, T., Huland, H., Graefen, M., ... Eichenauer, T. (2020). Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. WORLD J UROL, 38(9), 2185-2196. https://doi.org/10.1007/s00345-019-03017-w

Vancouver

Kind S, Büscheck F, Höflmayer D, Hube-Magg C, Kluth M, Tsourlakis MC et al. Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. WORLD J UROL. 2020 Sep;38(9):2185-2196. https://doi.org/10.1007/s00345-019-03017-w

Bibtex

@article{54967be0f51740d5931f0fb6e7ad7a4e,
title = "Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer",
abstract = "BACKGROUND: Claudin-1 is a membrane-tight junction protein and important for the sealing of the paracellular cleft in epithelial and endothelial cells. Differential expression of Claudin-1 is linked to disease outcome in various cancers.MATERIAL AND METHODS: To evaluate the potential relevance of Claudin-1 expression in prostate cancer, a tissue microarray containing samples of 17,747 tumors with annotated clinico-pathological and molecular data was immunohistochemically analyzed for Claudin-1 expression.RESULTS: In normal prostate, glandular cells were always Claudin-1-negative while there was a strong staining of gland-surrounding basal cells. In contrast to normal prostatic glands, a positive Claudin-1 immunostaining, was found, however, in 38.7% of 12,441 interpretable cancers and was considered weak in 12.7%, moderate in 13.2%, and strong in 12.8% of cases. Positive Claudin-1 immunostaining was associated with favorable tumor features like low pT (p = 0.0032), low Gleason grade (p< 0.0001), and a reduced risk of PSA recurrence (p = 0.0005). A positive Claudin-1 staining was markedly more frequent in ERG-positive (63%) than in ERG-negative cancers (23%; p < 0.0001). Subset analyses revealed that all associations of Claudin-1 expression and favorable phenotype and prognosis were driven by ERG-positive cancers. Multivariate analyses revealed, however, that even in ERG-positive cancers, the prognostic impact of high Claudin-1 expression was not independent of established clinico-pathological parameters. Comparison with 12 previously analyzed chromosomal deletions identified conspicuous associations with PTEN and 12p13 deletions potentially indicating functional interactions.CONCLUSION: These data identify a peculiar role for Claudin-1 in prostate cancer. The protein is overexpressed in a fraction of prostate cancers and increased Claudin-1 expression levels predict a favorable prognosis in ERG-positive cancer.",
author = "Simon Kind and Franziska B{\"u}scheck and Doris H{\"o}flmayer and Claudia Hube-Magg and Martina Kluth and Tsourlakis, {Maria Christina} and Stefan Steurer and Clauditz, {Till S} and Luebke, {Andreas M} and Eike Burandt and Waldemar Wilczak and Andrea Hinsch and David Dum and S{\"o}ren Weidemann and Christoph Fraune and Burkhard Beyer and Thomas Steuber and Hartwig Huland and Markus Graefen and Margit Fisch and Ronald Simon and Guido Sauter and Thorsten Schlomm and Sarah Minner and Till Eichenauer",
year = "2020",
month = sep,
doi = "10.1007/s00345-019-03017-w",
language = "English",
volume = "38",
pages = "2185--2196",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "9",

}

RIS

TY - JOUR

T1 - Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer

AU - Kind, Simon

AU - Büscheck, Franziska

AU - Höflmayer, Doris

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Tsourlakis, Maria Christina

AU - Steurer, Stefan

AU - Clauditz, Till S

AU - Luebke, Andreas M

AU - Burandt, Eike

AU - Wilczak, Waldemar

AU - Hinsch, Andrea

AU - Dum, David

AU - Weidemann, Sören

AU - Fraune, Christoph

AU - Beyer, Burkhard

AU - Steuber, Thomas

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Fisch, Margit

AU - Simon, Ronald

AU - Sauter, Guido

AU - Schlomm, Thorsten

AU - Minner, Sarah

AU - Eichenauer, Till

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: Claudin-1 is a membrane-tight junction protein and important for the sealing of the paracellular cleft in epithelial and endothelial cells. Differential expression of Claudin-1 is linked to disease outcome in various cancers.MATERIAL AND METHODS: To evaluate the potential relevance of Claudin-1 expression in prostate cancer, a tissue microarray containing samples of 17,747 tumors with annotated clinico-pathological and molecular data was immunohistochemically analyzed for Claudin-1 expression.RESULTS: In normal prostate, glandular cells were always Claudin-1-negative while there was a strong staining of gland-surrounding basal cells. In contrast to normal prostatic glands, a positive Claudin-1 immunostaining, was found, however, in 38.7% of 12,441 interpretable cancers and was considered weak in 12.7%, moderate in 13.2%, and strong in 12.8% of cases. Positive Claudin-1 immunostaining was associated with favorable tumor features like low pT (p = 0.0032), low Gleason grade (p< 0.0001), and a reduced risk of PSA recurrence (p = 0.0005). A positive Claudin-1 staining was markedly more frequent in ERG-positive (63%) than in ERG-negative cancers (23%; p < 0.0001). Subset analyses revealed that all associations of Claudin-1 expression and favorable phenotype and prognosis were driven by ERG-positive cancers. Multivariate analyses revealed, however, that even in ERG-positive cancers, the prognostic impact of high Claudin-1 expression was not independent of established clinico-pathological parameters. Comparison with 12 previously analyzed chromosomal deletions identified conspicuous associations with PTEN and 12p13 deletions potentially indicating functional interactions.CONCLUSION: These data identify a peculiar role for Claudin-1 in prostate cancer. The protein is overexpressed in a fraction of prostate cancers and increased Claudin-1 expression levels predict a favorable prognosis in ERG-positive cancer.

AB - BACKGROUND: Claudin-1 is a membrane-tight junction protein and important for the sealing of the paracellular cleft in epithelial and endothelial cells. Differential expression of Claudin-1 is linked to disease outcome in various cancers.MATERIAL AND METHODS: To evaluate the potential relevance of Claudin-1 expression in prostate cancer, a tissue microarray containing samples of 17,747 tumors with annotated clinico-pathological and molecular data was immunohistochemically analyzed for Claudin-1 expression.RESULTS: In normal prostate, glandular cells were always Claudin-1-negative while there was a strong staining of gland-surrounding basal cells. In contrast to normal prostatic glands, a positive Claudin-1 immunostaining, was found, however, in 38.7% of 12,441 interpretable cancers and was considered weak in 12.7%, moderate in 13.2%, and strong in 12.8% of cases. Positive Claudin-1 immunostaining was associated with favorable tumor features like low pT (p = 0.0032), low Gleason grade (p< 0.0001), and a reduced risk of PSA recurrence (p = 0.0005). A positive Claudin-1 staining was markedly more frequent in ERG-positive (63%) than in ERG-negative cancers (23%; p < 0.0001). Subset analyses revealed that all associations of Claudin-1 expression and favorable phenotype and prognosis were driven by ERG-positive cancers. Multivariate analyses revealed, however, that even in ERG-positive cancers, the prognostic impact of high Claudin-1 expression was not independent of established clinico-pathological parameters. Comparison with 12 previously analyzed chromosomal deletions identified conspicuous associations with PTEN and 12p13 deletions potentially indicating functional interactions.CONCLUSION: These data identify a peculiar role for Claudin-1 in prostate cancer. The protein is overexpressed in a fraction of prostate cancers and increased Claudin-1 expression levels predict a favorable prognosis in ERG-positive cancer.

U2 - 10.1007/s00345-019-03017-w

DO - 10.1007/s00345-019-03017-w

M3 - SCORING: Journal article

C2 - 31745645

VL - 38

SP - 2185

EP - 2196

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 9

ER -